Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure

This publication has 16 references indexed in Scilit:

• Sustained Hemodynamic Effects of Intravenous Levosimendan
  Circulation, 2003
• Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial
  The Lancet, 2002
• Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure
  The Journal of Clinical Pharmacology, 2002
• A glossary of circulating cytokines in chronic heart failure
  European Journal of Heart Failure, 2001
• Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure
  Circulation, 2000
• Elevated circulating levels and cardiac secretion of soluble fas ligand in patients with congestive heart failure
  The American Journal of Cardiology, 1999
• Influence of the Novel Inotropic Agent Levosimendan on Isometric Tension and Calcium Cycling in Failing Human Myocardium
  Circulation, 1998
• Serum Levels of Soluble Form of Fas Molecule in Patients with Congestive Heart Failure
  The American Journal of Cardiology, 1997
• Basic Mechanisms in Congestive Heart Failure
  Chest, 1994
• Relation of left ventricular shape, function and wall stress in man
  The American Journal of Cardiology, 1974